Qiagen N.V. (NASDAQ:QGEN)‘s stock had its “hold” rating reiterated by equities researchers at Cowen and Company in a note issued to investors on Friday. They presently have a $33.00 price objective on the stock. Cowen and Company’s price target would indicate a potential downside of 2.08% from the stock’s previous close.
QGEN has been the subject of a number of other research reports. Deutsche Bank AG reaffirmed a “buy” rating on shares of Qiagen N.V. in a research report on Monday, July 31st. Barclays PLC reaffirmed an “overweight” rating and issued a $37.00 target price (up previously from $33.00) on shares of Qiagen N.V. in a research report on Monday, July 17th. Zacks Investment Research downgraded shares of Qiagen N.V. from a “buy” rating to a “hold” rating in a research report on Monday, October 16th. Independent Research GmbH raised shares of Qiagen N.V. from a “sell” rating to a “hold” rating in a research report on Tuesday, August 1st. Finally, BidaskClub downgraded shares of Qiagen N.V. from a “buy” rating to a “hold” rating in a research report on Friday, August 4th. Nine analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Qiagen N.V. currently has a consensus rating of “Hold” and an average target price of $33.28.
Qiagen N.V. (NASDAQ QGEN) traded down $0.56 during trading hours on Friday, reaching $33.70. 1,319,182 shares of the company’s stock were exchanged, compared to its average volume of 1,666,568. The firm has a market capitalization of $7.68 billion, a P/E ratio of 27.86 and a beta of 1.13.
COPYRIGHT VIOLATION NOTICE: This piece was first posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.com-unik.info/2017/11/03/qiagen-n-v-qgen-stock-rating-reaffirmed-by-cowen-and-company.html.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Fox Run Management L.L.C. purchased a new position in shares of Qiagen N.V. during the 3rd quarter valued at $753,000. Airain ltd purchased a new position in shares of Qiagen N.V. during the 2nd quarter valued at $1,390,000. Neuberger Berman Group LLC lifted its stake in shares of Qiagen N.V. by 22.6% during the 2nd quarter. Neuberger Berman Group LLC now owns 1,349,457 shares of the company’s stock valued at $45,247,000 after buying an additional 249,176 shares in the last quarter. Prudential Financial Inc. purchased a new position in shares of Qiagen N.V. during the 1st quarter valued at $207,000. Finally, Marshall Wace North America L.P. purchased a new position in shares of Qiagen N.V. during the 2nd quarter valued at $5,195,000. Institutional investors own 60.35% of the company’s stock.
Qiagen N.V. Company Profile
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.
What are top analysts saying about Qiagen N.V.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Qiagen N.V. and related companies.